The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications
- Author
- Leen De Rycke, Dominique Baeten (UGent) , Elli Kruithof, Filip Van den Bosch (UGent) , Eric Veys (UGent) and Filip De Keyser (UGent)
- Organization
- Abstract
- Since the first proof of efficacy of TNFalpha blockade, both the number of patients treated worldwide and the number of indications for treatment with TNFalpha blockers have grown steadily. Surprisingly, the profound immunomodulation induced by anti-TNFalpha therapy is associated with a relatively low incidence of immune-related complications such as lupus-like syndromes and demyelinating disease. This contrasts sharply with the prominent induction of autoantibodies such as antinuclear antibodies (ANA) and anti-dsDNA antibodies during TNFalpha blockade. Although this phenomenon has been recognized for several years, the clinical and biological implications are not yet fully understood. In this review, recent studies analysing the effect of TNFalpha blockade (infliximab and etanercept) on the ANA profile in autoimmune arthritis will be discussed. Taken together, these reports indicate that the prominent ANA and anti-dsDNA autoantibody response is 1) not a pure class effect of TNFalpha blockers, 2) independent of the disease background, 3) largely restricted to the induction of short-term IgM anti-dsDNA antibodies, and 4) not. associated with other serological or clinically relevant signs of lupus. Nevertheless, a careful follow-up of patients treated with TNFalpha blockers remains mandatory, including monitoring for lupus-like characteristics.
- Keywords
- antinuclear antibodies, anti-dsDNA antibodies, etanercept, infliximab, lupus-like symptoms, SYSTEMIC-LUPUS-ERYTHEMATOSUS, NECROSIS-FACTOR-ALPHA, INFLIXIMAB INDUCES APOPTOSIS, RHEUMATOID-ARTHRITIS, MONOCLONAL-ANTIBODY, CONCOMITANT METHOTREXATE, SULFASALAZINE TREATMENT, NUCLEAR ANTIGENS, SYNOVIAL TISSUE, CROHNS-DISEASE
Downloads
-
(...).pdf
- full text
- |
- UGent only
- |
- |
- 146.36 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-329384
- MLA
- De Rycke, Leen, et al. “The Effect of TNFalpha Blockade on the Antinuclear Antibody Profile in Patients with Chronic Arthritis: Biological and Clinical Implications.” LUPUS, vol. 14, no. 12, 2005, pp. 931–37, doi:10.1191/0961203305lu2240rr.
- APA
- De Rycke, L., Baeten, D., Kruithof, E., Van den Bosch, F., Veys, E., & De Keyser, F. (2005). The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. LUPUS, 14(12), 931–937. https://doi.org/10.1191/0961203305lu2240rr
- Chicago author-date
- De Rycke, Leen, Dominique Baeten, Elli Kruithof, Filip Van den Bosch, Eric Veys, and Filip De Keyser. 2005. “The Effect of TNFalpha Blockade on the Antinuclear Antibody Profile in Patients with Chronic Arthritis: Biological and Clinical Implications.” LUPUS 14 (12): 931–37. https://doi.org/10.1191/0961203305lu2240rr.
- Chicago author-date (all authors)
- De Rycke, Leen, Dominique Baeten, Elli Kruithof, Filip Van den Bosch, Eric Veys, and Filip De Keyser. 2005. “The Effect of TNFalpha Blockade on the Antinuclear Antibody Profile in Patients with Chronic Arthritis: Biological and Clinical Implications.” LUPUS 14 (12): 931–937. doi:10.1191/0961203305lu2240rr.
- Vancouver
- 1.De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys E, De Keyser F. The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications. LUPUS. 2005;14(12):931–7.
- IEEE
- [1]L. De Rycke, D. Baeten, E. Kruithof, F. Van den Bosch, E. Veys, and F. De Keyser, “The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications,” LUPUS, vol. 14, no. 12, pp. 931–937, 2005.
@article{329384, abstract = {{Since the first proof of efficacy of TNFalpha blockade, both the number of patients treated worldwide and the number of indications for treatment with TNFalpha blockers have grown steadily. Surprisingly, the profound immunomodulation induced by anti-TNFalpha therapy is associated with a relatively low incidence of immune-related complications such as lupus-like syndromes and demyelinating disease. This contrasts sharply with the prominent induction of autoantibodies such as antinuclear antibodies (ANA) and anti-dsDNA antibodies during TNFalpha blockade. Although this phenomenon has been recognized for several years, the clinical and biological implications are not yet fully understood. In this review, recent studies analysing the effect of TNFalpha blockade (infliximab and etanercept) on the ANA profile in autoimmune arthritis will be discussed. Taken together, these reports indicate that the prominent ANA and anti-dsDNA autoantibody response is 1) not a pure class effect of TNFalpha blockers, 2) independent of the disease background, 3) largely restricted to the induction of short-term IgM anti-dsDNA antibodies, and 4) not. associated with other serological or clinically relevant signs of lupus. Nevertheless, a careful follow-up of patients treated with TNFalpha blockers remains mandatory, including monitoring for lupus-like characteristics.}}, author = {{De Rycke, Leen and Baeten, Dominique and Kruithof, Elli and Van den Bosch, Filip and Veys, Eric and De Keyser, Filip}}, issn = {{0961-2033}}, journal = {{LUPUS}}, keywords = {{antinuclear antibodies,anti-dsDNA antibodies,etanercept,infliximab,lupus-like symptoms,SYSTEMIC-LUPUS-ERYTHEMATOSUS,NECROSIS-FACTOR-ALPHA,INFLIXIMAB INDUCES APOPTOSIS,RHEUMATOID-ARTHRITIS,MONOCLONAL-ANTIBODY,CONCOMITANT METHOTREXATE,SULFASALAZINE TREATMENT,NUCLEAR ANTIGENS,SYNOVIAL TISSUE,CROHNS-DISEASE}}, language = {{eng}}, number = {{12}}, pages = {{931--937}}, title = {{The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications}}, url = {{http://doi.org/10.1191/0961203305lu2240rr}}, volume = {{14}}, year = {{2005}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: